AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03086486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200mg tablets
Study NCT01344070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: one of the 15 drugs listed below
Description: single, oral, immediate-release, non-combinational generic formulation c
Study NCT04033783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6MWT - accompanied
Description: Assessor walks behind the patient
Study NCT04033783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6MWT - not accompanied
Description: Assessor does not walk behind the patient
Study NCT00567411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine 0.1%
Description: 1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
Study NCT00567411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apraclonidine 0.5%
Description: 1 drop applied 1 hour prior to SLT
Study NCT01835002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal electrostimulation
Description: Weekly stimulation for 30 minutes with current of TES delivered of 150% of the individual phosphene threshold.
Study NCT02240602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 1.00 mg dose
Description: Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
Study NCT02240602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 0.03 mg/kg dose
Description: Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
Study NCT02240602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone, 0.02 mg/kg dose
Description: intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
Study NCT00873184 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Massage Therapy
Description: The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
Study NCT04165629 — intervention group
Intervention type: DRUG
Intervention: Aspirin 300mg and Clopidogrel 300mg
Description: Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
Study NCT04517643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therasphere Therapy
Description: TheraSphere is a radiotherapy treatment for primary and secondary liver neoplasia. This is an imaging study that will examine 3-5 patients who have been treated for metastatic colorectal cancer in the liver using TheraSphere®. Participation in the study involves an additional post-treatment SPECT/CT or PET/CT scan at (0-6) hours.
Study NCT01007838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training programme
Description: Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
Study NCT01007838 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham exercise
Description: Lower body stretching exercise using the easiest rehabilitation elastic Theraband
Study NCT01007838 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
Study NCT04348006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 3.5 MG
Description: VCD protocol~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* C, Cyclophosphamide: 300 mg/m2 IV over 30 min (day 1, 8, 15)~* D, Dexamethasone oral: 40mg (days 1 to 4)~VRD protocol:~* V, Alvocade®: Day 1, 4, 8, 11 (1.3 mg/m2 SC)~* R, Lenalid® cap 25 mg po (day 1 to 21)~* D, Dexamethasone oral: 40mg (days 1 to 4)
Study NCT02574689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIPP
Description: The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
Study NCT02574689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness contact control
Description: Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials.
Study NCT03147534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InstaTemp MD
Description: The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
Study NCT03147534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Welch Allyn, rectal
Description: The Welch Allyn rectal thermometer is intended to measure human body temperature.
Study NCT03161028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoic acid
Description: 1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
Study NCT03161028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
Study NCT03147534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Welch Allyn, oral
Description: The Welch Allyn oral thermometer is intended to measure human body temperature.
Study NCT03147534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Covidien, tympanic
Description: The Covidien tympanic thermometer is intended to measure human body temperature.
Study NCT03581838 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observed eating session
Description: Eating a Jimmy Johns turkey or vegetarian sandwich
Study NCT01616251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake
Description: 4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
Study NCT03052816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ice T
Description: Ice/Tylenol/Toradol with dilaudid for breakthrough
Study NCT03052816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin/Percocet/Dilaudid for breakthrough
Description: Standard regimen
Study NCT01359228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin (XIFAXAN)
Description: Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
Study NCT01359228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet three times a day for 14 days.
Study NCT01533142 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass
Study NCT01533142 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
Study NCT00999297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dihydrocapsiate
Description: Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Study NCT00999297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dihydrocapsiate
Description: Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Study NCT00562991 — intervention group
Intervention type: DEVICE
Intervention: measurement of exhaled NO is used to guide treatment
Description: exhaled NO
Study NCT03588936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (.25 mg/kg)
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Study NCT03588936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive 2 doses of tocilizumab
Study NCT03588936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (.5 mg/kg)
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Study NCT00649402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
Description: 10/120mg, single dose fed
Study NCT00649402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel® Capsules 10 mg/20 mg
Description: 10/20mg, single dose fed
Study NCT03413709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family Formation Program
Description: The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
Study NCT01392209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bevacizumab & Stereotactic Radiotherapy
Description: Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
Study NCT04014569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPSA Algorithm
Description: Insulin dosing will be adjusted using the MPSA Algorithm
Study NCT03940118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter secretion suctioning
Description: Catheter secretion suctioning with prior nebulization of hypertonic saline
Study NCT03940118 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Secretion suctioning + hypertonic saline
Description: Catheter secretion suctioning with prior nebulization of hypertonic saline
Study NCT03940118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ins-exsufflation
Description: Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
Study NCT03940118 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ins-exsufflation + Hypertonic saline
Description: Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
Study NCT01183455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aralast NP
Description: Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
Study NCT01183455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV infusions of placebo once a week for 12 weeks.
Study NCT05399290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Hyclate
Description: 100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
Study NCT05399290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate
Description: 100 mg vs 20 mg doxycycline hyclate BID for 12 weeks
Study NCT04072263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
Study NCT04072263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa 2A
Description: Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
Study NCT04072263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy i.v.
Study NCT04072263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy i.v.
Study NCT00767767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV Saline infusion for 2 hours.
Study NCT00767767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 0.45mcg/mL
Description: IV Propofol infusion for 2 hours.
Study NCT00767767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 0.90mcg/mL
Description: IV Propofol infusion for 2 hours.
Study NCT00767767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental 1.5mcg/mL
Description: IV Thiopental 1.5mcg/mL infusion for 2 hours
Study NCT00767767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental 3mcg/mL
Description: IV Thiopental 3mcg/mL infusion for 2 hours
Study NCT00478686 — intervention group
Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: 5 to 7.5 milliliter (mL) Blood Sample
Study NCT01366729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraTogs
Description: Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
Study NCT01366729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cane walking
Description: All walking activities must take place with cane from waking until sleeping
Study NCT04107207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ginger Kombucha
Description: Craft Ginger Kombucha, a fermented black tea
Study NCT04107207 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ginger Water
Description: Placebo
Study NCT00223249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine
Study NCT00223249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Study NCT03100175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: strength training for upper and lower limbs fitness and balance work out
Study NCT04167137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1891
Description: SYNB1891 was administered as an IT injection over a dose range of 1 x 10\^6 to 3 x 10\^8 live cells in Arm 1 and 1 x 10\^7 to 3 x 10\^7 in Arm 2.
Study NCT04167137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was administered in accordance with its recommended dose and schedule (1200 mg IV Q3W).
Study NCT04202133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW (formerly Weight Watchers)
Description: The WW intervention will consist of weekly group workshops for 16 weeks with WW Coaches and Guides.
Study NCT04202133 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered the WW intervention
Study NCT00525096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets twice a day per os
Study NCT00525096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 2\*200 mg tablets twice a day per os
Study NCT00525096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane 25 mg per day per os
Study NCT00525096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Exemestane 25 mg per day per os
Study NCT03265782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
Study NCT03265782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
Study NCT01963156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescription synchronization
Description: Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point.
Study NCT01849419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subjects (MDMA)
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
Study NCT01849419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subjects (oxytocin)
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
Study NCT01849419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subjects (placebo)
Description: This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
Study NCT02283632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jejunal Diversion
Description: The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
Study NCT01453608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject (ferric carboxymaltose)
Description: Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
Study NCT01453608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Subjects will receive Placebo (saline) intravenously on Day 0
Study NCT01072253 — intervention group
Intervention type: PROCEDURE
Intervention: eye amputation
Study NCT00306540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate
Description: oral flexible dose
Study NCT00306540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine fumarate placebo
Description: oral 0 mg
Study NCT01199562 — intervention group
Intervention type: PROCEDURE
Intervention: infection prophylaxis and management
Description: Undergo infection prophylaxis and management
Study NCT01199562 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01199562 — intervention group
Intervention type: OTHER
Intervention: flow cytometry
Description: Correlative studies
Study NCT01199562 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: Correlative studies
Study NCT01199562 — intervention group
Intervention type: GENETIC
Intervention: RNA analysis
Description: Correlative studies